Precision-engineered contract manufacturing services and standardized botanical active compounds developed under rigorous international compliance standards.
Navigating the paradigm shift from empirical herbal preparations to molecular-targeted, evidence-based phytopharmaceuticals under global pharmacopoeia harmonization.
International pharmaceutical enterprises are systematically de-risking raw material volatility by anchoring R&D within China's geo-authentic botanical clusters. Modernized processing hubs reduce heavy-metal contaminants and pesticide residues below strict ICH Q3D and EP/USP limits, converting agricultural unpredictability into cGMP-compliant standardized chemical inputs.
The historic bottleneck of botanical medicine—uncertain synergy and complex polychemical matrices—is resolved through multi-omics profiling and network pharmacology. China's top tier manufacturers now provide clear downstream mechanistic attribution, mapping isolated secondary metabolites to specific cytokine suppression or receptor activation pathways.
Decoupling clinical research from industrial formulation creates massive translation loss. Integrated Chinese platforms consolidate preclinical in vitro screening, tox-pathology, pilot extraction, and commercial scale solid/liquid dosage manufacturing into a singular audited pipeline, trimming new drug candidate timelines by 30 to 45%.
Over 14+ years of dedicated natural medicine CRO & CDMO stewardship underpins our clinical validation and production capabilities in Changsha, Hunan.
Delivering reproducible analytical and therapeutic continuity across every tier of the new botanical medicine lifecycle.
High-throughput isolation and bioassay-guided fractionation identify elite lead compounds (alkaloids, flavonoids, polysaccharides). Quantitative geographic fingerprinting identifies peak chemotype windows based on harvest ecology, altitude, and seasonal weather patterns.
Full development and validation of analytical monographs utilizing High-Performance Thin-Layer Chromatography (HPTLC), HPLC-MS/MS, and GC-FID. Establishing reference standards, marker stability kinetics, and fingerprint similitude indices that withstand regulatory scrutiny.
Comprehensive toxicity packages conforming to GLP paradigms: Acute Oral LD50, 28/90-day repeat-dose subchronic toxicity, bacterial reverse mutation (Ames test), in vitro chromosomal aberration, and target receptor engagement profiling in rodent efficacy models.
Human clinical trial authorization support, protocol architecture, dynamic PK/PD parameter assessment, and blinded placebo-controlled clinical validations. Designing proof-of-concept human trials for OTC consumer claims through formal NDA registrational packages.
Direct scale-up from benchtop reflux extraction to metric-ton automated closed-loop continuous extraction lines. Advanced membrane ultrafiltration, macroporous resin column purification, freeze drying, and spray crystallization ensuring stable, bioavailable physical powder/oil forms.
Overcoming hygroscopicity, oxidation, and low bioavailability with modern formulation techniques. Full contract manufacturing for oral solutions, hard-gel capsules, enteric softgels, multilayer tablets, micro-granules, and reconstitutable effervescent blends.
Harmonizing Chinese natural medicine manufacturing output with target regulatory authorities across the United States, European Union, APAC, and Middle East.
Aligning Chemistry, Manufacturing, and Controls (CMC) dossiers with the US FDA Botanical Drug Development Guidance. Comprehensive Raw Material DMF filing, batch-to-batch chemical equivalence testing, and residual solvent clearance complying with USP <467>.
Preparation of Traditional Herbal Medicinal Product (THMPD) and Well-Established Use documentation under EMA directives. Continuous tracking of pyrrolizidine alkaloids (PA), aflatoxins (B1, B2, G1, G2), and heavy metals under European Pharmacopoeia (Ph. Eur.) limits.
All contract R&D agreements operate within legally ring-fenced NDA environments. Client IP, customized fraction isolation parameters, chemical matrices, and synthetic routes remain the exclusive commercial property of the commissioning buyer.
Complete GACP (Good Agricultural and Collection Practices) traceability back to GPS-tagged plantation coordinates. Systematic testing profiles for over 450 multiresidue pesticides and organochlorines across every harvest batch.
Engineering customized natural chemistry solutions tailored to stringent therapeutic, nutraceutical, and dermaceutical market demands.
Developing premium, clean-label nutraceutical actives with clinically substantiated bioavailability. Serving metabolic health (glycemic & lipid moderation), neuro-support (cognitive & sleep adaptation), and immune-modulatory formulations that exceed modern consumer standards.
Supplying standardized botanical drug substances (BDS) for pharmaceutical IND/NDA pathways. Proven clinical trial support in cardiovascular indications, post-viral pulmonary recovery, anti-inflammatory cascades, and oncology-supportive adjunctive botanical therapies.
High-purity botanical actives optimized for transdermal penetration, tyrosinase inhibition, accelerated fibroblast collagen synthesis, and biological UV defense. Backed by human patch safety data and in vitro cellular antioxidant biomarkers.
How artificial intelligence, synthetic biology, and green process chemistry are redefining global natural medicine contract manufacturing.
Integrating machine learning algorithms to screen secondary botanical metabolites against crystallographic enzyme targets. Reducing target identification cycles from months to days while pinpointing minor isomers with maximum pharmacodynamic potency.
Eliminating organic solvent dependencies through multi-stage industrial supercritical CO₂ fluid fractionation. Reducing carbon footprint and chemical waste while generating ultra-pure heat-sensitive volatile oils and thermolabile phytocannabinoids/terpenes.
Solving the historic solubility and gastric degradation barriers of botanical compounds (such as polyphenols and curcumins) via nano-liposomal encapsulation and cyclodextrin complexation for 5x to 10x oral bioavailability enhancement.
Combining natural plant tissue cultures with engineered microbial fermentation to synthesize ultra-rare, endangered plant actives (e.g., specific ginsenosides, taxoids) at metric scale without threatening wild biodiversity reserves.
MedGence (Yineng Pharma) serves as the trusted research and development engine behind China's most respected pharmaceutical manufacturers and tertiary medical centers.
China Beijing Tongrentang Group
China Resources Sanjiu Medical
Sunflower Pharmaceutical Group
Livzon Pharmaceutical Group
Dihon Pharmaceutical Group
Golden Throat Holdings Group
Yangtzi River Pharmaceutical
Humanwell Healthcare Group
Shuguang Hospital Affiliated to Shanghai TCM
Second Xiangya Hospital Central South Univ
First Hospital of Hunan Univ of TCM
Hunan Province Directly Affiliated TCM Hospital
Direct technical answers addressing technology transfer, international testing standards, batch stability, and IP security.
Select your target research phase or request technical specifications directly from our scientific consultation committee.
